DE60009319D1 - Substituierte n-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamid-derivative zur erhöhung der pyruvatdehydrogenaseaktivität - Google Patents

Substituierte n-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamid-derivative zur erhöhung der pyruvatdehydrogenaseaktivität

Info

Publication number
DE60009319D1
DE60009319D1 DE60009319T DE60009319T DE60009319D1 DE 60009319 D1 DE60009319 D1 DE 60009319D1 DE 60009319 T DE60009319 T DE 60009319T DE 60009319 T DE60009319 T DE 60009319T DE 60009319 D1 DE60009319 D1 DE 60009319D1
Authority
DE
Germany
Prior art keywords
trifluorpropanamide
hydroxy
phenyl
derivative
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60009319T
Other languages
English (en)
Other versions
DE60009319T2 (de
Inventor
Roger John Butlin
Janet Elizabeth Pease
Michael Howard Block
Thorsten Nowak
Jeremy Nicholas Burrows
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9920814.2A external-priority patent/GB9920814D0/en
Priority claimed from GB0006641A external-priority patent/GB0006641D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60009319D1 publication Critical patent/DE60009319D1/de
Application granted granted Critical
Publication of DE60009319T2 publication Critical patent/DE60009319T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE60009319T 1999-09-04 2000-08-30 Substituierte n-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamid-derivative zur erhöhung der pyruvatdehydrogenaseaktivität Expired - Fee Related DE60009319T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9920814 1999-09-04
GBGB9920814.2A GB9920814D0 (en) 1999-09-04 1999-09-04 Chemical compounds
GB0006641A GB0006641D0 (en) 2000-03-21 2000-03-21 Chemical compounds
GB0006641 2000-03-21
PCT/GB2000/003314 WO2001017956A1 (en) 1999-09-04 2000-08-30 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity

Publications (2)

Publication Number Publication Date
DE60009319D1 true DE60009319D1 (de) 2004-04-29
DE60009319T2 DE60009319T2 (de) 2005-03-31

Family

ID=26243905

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009319T Expired - Fee Related DE60009319T2 (de) 1999-09-04 2000-08-30 Substituierte n-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamid-derivative zur erhöhung der pyruvatdehydrogenaseaktivität

Country Status (32)

Country Link
US (1) US6689909B1 (de)
EP (1) EP1214296B1 (de)
JP (1) JP2003508515A (de)
KR (1) KR100692232B1 (de)
CN (1) CN1235877C (de)
AR (1) AR035163A1 (de)
AT (1) ATE262507T1 (de)
AU (1) AU760061B2 (de)
BG (1) BG65099B1 (de)
BR (1) BR0013694A (de)
CA (1) CA2381581A1 (de)
CO (1) CO5190690A1 (de)
CZ (1) CZ2002773A3 (de)
DE (1) DE60009319T2 (de)
DK (1) DK1214296T3 (de)
EE (1) EE05080B1 (de)
ES (1) ES2216940T3 (de)
HK (1) HK1045496B (de)
HU (1) HUP0202725A3 (de)
IL (2) IL148111A0 (de)
IS (1) IS2069B (de)
MX (1) MXPA02002319A (de)
MY (1) MY127036A (de)
NO (1) NO20021040L (de)
NZ (1) NZ517147A (de)
PL (1) PL353887A1 (de)
PT (1) PT1214296E (de)
RU (1) RU2255085C2 (de)
SK (1) SK286774B6 (de)
TR (1) TR200200550T2 (de)
TW (1) TW577867B (de)
WO (1) WO2001017956A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399753T1 (de) 1999-09-04 2008-07-15 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
GB0012012D0 (en) * 2000-05-19 2000-07-05 Astrazeneca Ab Chemical compound
GB0120471D0 (en) * 2001-08-23 2001-10-17 Astrazeneca Ab Chemical compounds
WO2003055850A1 (fr) * 2001-12-27 2003-07-10 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs de la production/secretion de la proteine amyloide-$g(b)
US9388164B2 (en) 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
NZ707778A (en) 2012-11-08 2019-03-29 Agios Pharmaceuticals Inc Therapeutic compounds and compositions and their use as pkm2 modulators
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
BR112020003254A2 (pt) 2017-08-15 2020-10-27 Agios Pharmaceuticals, Inc. moduladores da piruvato quinase e uso destes
CN109096186B (zh) * 2018-09-29 2020-08-04 中南大学 一种2-芳磺酰基喹啉衍生物的合成方法
JPWO2023032940A1 (de) * 2021-09-01 2023-03-09

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002309B1 (de) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilide, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische und tierärztliche Zusammensetzungen
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
AU8961382A (en) 1981-11-06 1983-05-12 Imperial Chemical Industries Plc Amide derivatives
US4537618A (en) 1982-05-26 1985-08-27 Ciba Geigy Corporation N-phenylsulfonyl-N'-pyrimidinylureas
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
EP0539329A1 (de) 1991-10-25 1993-04-28 Ciba-Geigy Ag Acetylen-Verbindungen, verwendbar als Leukotrien-Antagonisten
SE9103397D0 (sv) 1991-11-18 1991-11-18 Kabi Pharmacia Ab Nya substituerade salicylsyror
IL105558A (en) 1992-05-18 1998-04-05 Zeneca Ltd Tertiary carbinols with channel activity potassium process for their preparation and pharmaceutical preparations containing them
GB9305295D0 (en) * 1993-03-15 1993-05-05 Zeneca Ltd Therapeutic compounds
GB9309716D0 (en) 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
GB9310069D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Heterocyclic compounds
GB9310095D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
GB2278054A (en) 1993-05-18 1994-11-23 Zeneca Ltd Compounds for the treatment of urinary incontinence
GB9505082D0 (en) 1995-03-14 1995-05-03 Zeneca Ltd Medicament
GB9607458D0 (en) 1996-04-10 1996-06-12 Zeneca Ltd Enzymatic process for stereoselective preparation of therapeutic amides
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
HUP0202725A3 (en) 2005-04-28
EP1214296B1 (de) 2004-03-24
KR100692232B1 (ko) 2007-03-09
MY127036A (en) 2006-11-30
TR200200550T2 (tr) 2002-06-21
HK1045496A1 (en) 2002-11-29
TW577867B (en) 2004-03-01
AR035163A1 (es) 2004-05-05
ES2216940T3 (es) 2004-11-01
EE05080B1 (et) 2008-10-15
EE200200113A (et) 2003-06-16
NO20021040L (no) 2002-05-02
WO2001017956A1 (en) 2001-03-15
JP2003508515A (ja) 2003-03-04
EP1214296A1 (de) 2002-06-19
BG65099B1 (bg) 2007-02-28
PT1214296E (pt) 2004-08-31
CO5190690A1 (es) 2002-08-29
CZ2002773A3 (cs) 2002-06-12
AU760061B2 (en) 2003-05-08
MXPA02002319A (es) 2002-07-30
SK3002002A3 (en) 2002-07-02
DE60009319T2 (de) 2005-03-31
SK286774B6 (sk) 2009-05-07
CN1387509A (zh) 2002-12-25
IS2069B (is) 2005-11-15
AU6854300A (en) 2001-04-10
NO20021040D0 (no) 2002-03-01
HK1045496B (zh) 2004-10-21
BR0013694A (pt) 2002-05-21
RU2255085C2 (ru) 2005-06-27
ATE262507T1 (de) 2004-04-15
CN1235877C (zh) 2006-01-11
IL148111A0 (en) 2002-09-12
IL148111A (en) 2007-05-15
BG106520A (en) 2003-03-31
PL353887A1 (en) 2003-12-15
NZ517147A (en) 2003-11-28
DK1214296T3 (da) 2004-07-05
RU2002108508A (ru) 2004-01-20
CA2381581A1 (en) 2001-03-15
HUP0202725A2 (hu) 2003-01-28
US6689909B1 (en) 2004-02-10
KR20020067498A (ko) 2002-08-22
IS6285A (is) 2002-02-26

Similar Documents

Publication Publication Date Title
LU93311I2 (fr) Mancozèbe, valifenalate
DE60019577D1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
ITBO990522A0 (it) Rullo perfezionato per cingoli .
ID28483A (id) 2-(3,5-bis-trifluorometil-fenil)-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il)-isobutiramida
DE60009319D1 (de) Substituierte n-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamid-derivative zur erhöhung der pyruvatdehydrogenaseaktivität
HK1044934A1 (en) Amide compounds for the potentiation of cholinergic activity.
NO20023172D0 (no) 10, 11-difluormetylendioksycamptothecin-forbindelser med topoisomerase I inhibering
DE60000826D1 (de) 14.beta.,17-alpha-hydroxymethylandrostan derivate als androgene
IL160455A0 (en) Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
ES1044857Y (es) Somier perfeccionado desmontable.
SI1214296T1 (en) Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
ES1044451Y (es) Gavion perfeccionado.
ES1043677Y (es) Terrazo perfeccionado.
ES1044503Y (es) Maceta perfeccionada.
IT1306146B1 (it) Nebulizzatore perfezionato.
IT245087Y1 (it) Passalaccio perfezionato, particolarmente per calzature.
ES1041974Y (es) Adorno perfeccionado.
ES1043536Y (es) Calzado perfeccionado.
ES1045275Y (es) Urinario vertical perfeccionado.
ES1044266Y (es) Carta-sobre perfeccionada.
ES1044639Y (es) Cubierto perfeccionado.
DE60017150D1 (de) 1,4,5,6 -tetrahydropyrimidine-derivative als vitronectin-hemmer
ES1043175Y (es) Volquete perfeccionado.
ES1043111Y (es) Macetero rodante perfeccionado.
ES1044586Y (es) Limpiazapatos perfeccionado.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee